Plus Therapeutics (NASDAQ:PSTV) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a research note published on Thursday morning,Benzinga reports. D. Boral Capital currently has a $5.00 price target on the stock.

A number of other analysts have also commented on the company. HC Wainwright decreased their target price on Plus Therapeutics from $5.50 to $3.00 and set a “buy” rating for the company in a research report on Friday, June 27th. Maxim Group reduced their price objective on Plus Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Monday, August 18th. Wall Street Zen raised Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 16th. Ascendiant Capital Markets increased their target price on Plus Therapeutics from $20.00 to $20.50 and gave the stock a “buy” rating in a report on Thursday, June 5th. Finally, D Boral Capital upgraded shares of Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $7.88.

Plus Therapeutics Stock Up 3.5%

Plus Therapeutics stock opened at $0.43 on Thursday. Plus Therapeutics has a 12-month low of $0.16 and a 12-month high of $2.31. The firm’s fifty day moving average is $0.51 and its 200 day moving average is $0.58. The company has a market capitalization of $42.79 million, a PE ratio of -0.19 and a beta of 0.66.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.08. The company had revenue of $1.39 million during the quarter, compared to analyst estimates of $1.08 million. Sell-side analysts expect that Plus Therapeutics will post -2.3 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Robert P. Lenk acquired 110,000 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were purchased at an average cost of $0.49 per share, with a total value of $53,900.00. Following the acquisition, the director directly owned 139,327 shares of the company’s stock, valued at $68,270.23. The trade was a 375.08% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.79% of the company’s stock.

Institutional Trading of Plus Therapeutics

A hedge fund recently bought a new stake in Plus Therapeutics stock. Jane Street Group LLC purchased a new stake in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 117,454 shares of the company’s stock, valued at approximately $41,000. Jane Street Group LLC owned approximately 0.19% of Plus Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.